

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
29 March 2001 (29.03.2001)

PCT

(10) International Publication Number  
**WO 01/21823 A2**

- (51) International Patent Classification<sup>7</sup>: C12N 15/86 (74) Agents: ELSY, David et al.; Withers & Rogers, Goldings House, 2 Hays Lane, London SE1 2HW (GB).
- (21) International Application Number: PCT/GB00/03645
- (22) International Filing Date:  
22 September 2000 (22.09.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
9922283.8 22 September 1999 (22.09.1999) GB
- (71) Applicant (*for all designated States except US*): THE MATHILDA & TERENCE KENNEDY INSTITUTE OF RHEUMATOLOGY [GB/GB]; 1 Aspenlea Road, Hammersmith, London W6 8LH (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): FELDMAN, Marc [AU/GB]; 2 Church Road, London N6 4QT (GB). FOXWELL, Brian, Maurice, John [GB/GB]; 23 Lansdowne Road, Hownslow, Middlesex TW3 1LQ (GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— Without international search report and to be republished upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/21823 A2

(54) Title: ADENOVIRAL VECTORS

(57) Abstract: The invention relates to adenoviral vectors comprising a mammalian regulatory region such as a cytokine regulatory region and a reporter gene operatively linked to the cytokine promoter. Preferably, the cytokine promoter is a TNF $\alpha$  promoter or an IL-10 promoter. The application also discloses methods of studying cytokine promoter activity and to cells containing the adenoviral vectors.

## ADENOVIRAL VECTORS

The invention relates to adenoviral vectors, and in particular to adenoviral vectors comprising a mammalian regulatory region, such as a promoter, and a reporter gene operatively linked to the cytokine promoter. The invention also relates to cells containing the adenoviral vectors and to methods of using the adenoviral vectors.

Adenoviral vectors which are capable of carrying foreign DNA into cells are known in the art.

Adenoviruses exist as non-enveloped double-stranded DNA viruses. The adenovirus enters cells by a receptor-mediated endocytosis pathway. In the initial virus-receptor interaction, the adenovirus binds specific receptors present on the cell surface via fibres on its outer surface. Following attachment, the receptors with bound adenovirus cluster in coated pits, the virus is internalised within a clathrin-coated vesicle and, subsequently, into an endosomal vesicle, known as a receptosome or endosome. The adenovirus is ultimately transported to the nucleus where it directs synthesis of new nucleic acid and hence virus.

Adenovirus has been used as means of transporting DNA into cells. There are two means by which such transfer has been affected. Firstly, the adenovirus has been employed to facilitate the transfer of non-viral DNA either linked to the surface of the adenovirus or where the molecule is internalised, taken along within the adenoviral receptor-endosome complex. Secondly, the adenovirus has been employed to transfer non-viral molecules which are packaged within the adenovirus either in place of, or in addition to normal adenoviral genome. All systems have been used to take in exogenous nucleic acid placed within the double-stranded DNA genome of the virus. Such exogenous DNA has been placed under the control of a promoter to allow the exogenous nucleic acid to be transcribed.

The inventors have now produced adenoviral vectors comprising a mammalian regulatory sequence such as a cytokine promoter. Cytokines are peptide regulators of inflammatory and immune reactions. Substances considered as cytokines include, for example, interleukins 1-18, interferons, tumour necrosis factors (TNF), transforming growth factors (TGF),

platelet-derived growth factors, chemokines and colony-stimulating factors. Some compounds were sometimes previously known by the term "lymphokine".

Cytokines act in a complex interacting network on leucocytes, vascular endothelial cells, mast cells, haemopoietic stem cells, fibroblasts and osteoclasts, controlling proliferation, differentiation and/or activation through autocrine or paracrine mechanisms. Several cytokines, for example TNF- $\alpha$  and IL-1 are important inflammatory mediators and have been implicated in several chronic inflammatory and autoimmune diseases such as rheumatoid arthritis. The cytokines are being increasingly studied because of their importance in the formation of inflammatory and autoimmune diseases. Because the cytokines are involved in complex interconnecting reactions it is difficult to investigate the control of regulatory regions such as promoters or enhancers associated with the cytokines. The inventors realised that a cytokine promoter could be used to control a readily detectable reporter gene and allow the promoter to be studied. Furthermore, they recognised that adenovirus is a suitable vector because it enables the promoter-reporter gene construct to be inserted into a wide variety of cells including cultured cell-lines, normal cells such as macrophages, diseased tissue and primary cell-lines. The ability to insert a construct into primary cells is of particular importance because it allows the control of the promoter to be studied within, for example, diseased cells.

The use of adenovirus also had the unexpected benefit of allowing unexpectedly high levels of regulatory region-controlled reporter gene function and behaviour to be observed that were similar to the behaviour of the endogenous gene. These levels were far in excess of levels observed with other methods of inserting a cytokine regulatory region-reporter gene construct into cells. Furthermore, it has the advantage that, for the first time, cytokine promoters, such as TNF- $\alpha$  promoters, have been able to be studied in monocytic cells for the first time. It is expected that the high levels of expression observed means that such promoters can be studied in a variety of cells.

TNF $\alpha$  promoter-luciferase vectors have been produced by Udalova *et al* (J. Biol. Chem., 1998, Vol. 273, pages 21178-21186). However, the vector containing the construct, pXP-1,

can only be used in a limited number of cell types, and with low levels of expression of the promoter.

The invention provides an adenoviral vector comprising:

- a) a mammalian regulatory region; and
- b) a reporter gene operatively linked to the cytokine regulatory region (a).

The term "mammalian regulatory region" is intended to mean a region of DNA which, in its natural state, is upstream and/or downstream of a gene which it regulates. For example, it may be the promoter for the gene encoding a human oestrogen receptor.

The regulatory region may be a promoter or an enhancer region or a fragment of a region, such as an NF- $\kappa$ B binding site.

The regulatory region may regulate the expression of a cytokine gene. Preferably the cytokine promoter is an interleukin promoter such as IL-10. Preferably the IL-10 promoter has the sequence from NT 7 to NT 4046 of Genbank sequence number X78437, where NT 4023 is the transcription start site, as shown in Annex 2.

Alternatively the promoter may be derived from other genes that have application in inflammatory disease, such as IL-6 and MMP.

The cytokine promoter may also be the promoter for TNF $\alpha$ . More especially, the TNF $\alpha$  receptor is a human TNF $\alpha$  receptor, especially the TNF $\alpha$  promoter identified in Genbank Accession No. M16441. This is enclosed as Annex 1. This is also the promoter used in the Udilova paper (Supra). Most preferably the sequence used is encompassed within -1173 to +130 of the human TNF gene, where 1 is the transcriptional start site. The transcriptional start site is nucleotide 4094 in the Genbank Accession No. M16441. Hence, preferably the promoter sequence starts from 2921 of M16441.

Any suitable adenoviral vector can be utilised in the present invention. A "vector" is a molecule that serves to transfer nucleic acid of interest into a cell. Thus, the adenoviral

vector utilised in accordance with the present invention can encompass any adenoviral vector that is appropriate for the introduction of nucleic acids into eukaryotic cells and is capable of functioning as a vector as that term is understood by those of ordinary skill in the art.

The adenovirus can be any serotype of adenovirus and, preferably, is a serotype that can transduce and/or infect a human cell. The adenovirus may comprise a complete adenoviral virion consisting of a core of nucleic acid and a protein capsid. Alternatively, it may comprise a naked adenoviral genome or any other manifestation of adenovirus as described in the art which can be used to transfer a cytokine regulatory region operatively linked to a reporter gene. Alternatively the virion may contain minimal (packaging signal) adenoviral genome sequences. These "gutless" viruses are produced by methods known in the art.

The adenovirus employed for transfer of the regulatory region-reporter gene construct can be wildtype, that is replication-competent. However, it is not necessary that the genome of the employed adenovirus be intact. Indeed, the adenovirus can be rendered replication-deficient, by techniques known in the art.

The reporter gene is operatively linked to the mammalian regulatory region. By this we mean that the nucleic acid encoding the reporting gene is linked to the regulatory region in such a way that the regulatory region is capable of directing transcription of the reporter gene. The reporter gene may be any nucleic acid sequence encoding a detectable gene product. The gene product may be an untranslated RNA product, such as mRNA or antisense RNA. Such untranslated RNA may be detected by techniques known in the art such as PCR, Northern or Southern blots. Alternatively, the reporter gene may encode a polypeptide, such as protein or peptide, product. Polypeptide may be detected immunologically or by means of its biological activity. The reporter genes used may be any known in the art.

Preferably, the reporter gene is luciferase. Luciferase reporter genes are known in the art. They are usually derived from firefly (*Photinus pyralis*) or seapansy (*Renilla reniformis*). The luciferase enzyme catalyses a reaction using D-luciferin and ATP in the presence of oxygen and  $Mg^{2+}$  resulting in light emission. The luciferase reaction is quantitated using a

luminometer which measures light output. The assay may also include coenzyme A in reaction which provides a longer, sustained light reaction with greater sensitivity.

An alternative reporter gene to use is CAT (chloramphenicol acetyltransferase). This is a reporter gene which is well known in the art. CAT catalyses the transfer of the acetyl group from acetyl-CoA to the substrate chloramphenicol. The enzyme reaction can be quantitated by incubating cells or cell lysates with [<sup>14</sup>C] chloramphenicol and following product formation by physical separation with, for example, thin layer chromatography or organic extraction. Alternatively, the CAT protein can be quantitated using an enzyme-linked immunosorbent assay. Such an assay is available from, for example, Promega Corporation, Southampton, United Kingdom.

A further reporter system which may be used is *lacZ* gene from *E.coli*. This encodes the  $\beta$ -galactosidase enzyme. This catalyses the hydrolysis of  $\beta$ -galactoside sugars such as lactose. The enzymatic activity in cell extracts can be assayed with various specialised substrates, for example x-gal, which allow enzyme activity quantitation using a spectrophotometer, fluorometer or a luminometer.

The reporter gene may also be gfp (green fluorescent protein) or  $\beta$ -globin, which are also known in the art.

The adenoviral vector preferably includes suitable termination sequences known in the art to allow the transcription of the reporter gene to be successfully terminated. Suitably, the vector also comprises a polyadenylation sequence. Such sequences may be derived from the gene from which the regulatory region is derived or alternatively from other sources such as an SV40 late polyadenylation signal to allow secretion of the reporter gene product. The termination sequences and/or polyadenylation sequences may be operatively linked 3' to the reporter gene.

The adenoviral vector may additionally comprise, 3' to the reporter gene, a 3'-UTR (untranslated region). Preferably, the 3'-UTR is from a cytokine. Preferably, the 3'-UTR is from the human TNF gene. In particular, the 3'-UTR may be from sequence identified as

Genbank Accession No. M16441, especially the sequences encoding 1041NT to the 3' of NT6071 of M16441. The sequences referred to in the paper by Udalova *et al* (Supra). 3'-UTR regions are thought to be involved effecting the stability and translation of mRNA. It is therefore advantageous to incorporate a 3'-UTR region to enable the effect of the region to be studied.

The adenoviral vector may additionally comprise one or more sequences to enable it to be maintained or replicated within a suitable bacterial host vector, such as *Escherichia coli*. Such sequences are well known in the art and include, for example, a bacterial origin or replication such as fl ori. It may also include one or more genes to enable selection of bacteria comprising the adenoviral vector, such as ampicillin or tetracycline resistance genes known in the art.

The vector may additionally comprise a further reporter gene under the control of a constitutive or unregulated promoter such as CMV promoter. The further reporter gene will be different to the first reporter gene. It acts as an internal control, allowing variations, such as the amount of vector within each cell, to be taken into account.

A further aspect of the invention provides a method of studying mammalian regulatory region activity comprising inserting an adenoviral vector according to the invention into a cell and measuring the amount of reporter gene product produced by the mammalian regulatory region encoded by the adenoviral vector. The cell into which the vector has been inserted may be exposed to one or more inhibitors or activators of the mammalian regulatory region. Cells may or may not be activated with a stimulus such as lipopolysaccharide

Alternatively, the activity in a diseased cell, for example from rheumatoid arthritic joints, may be compared with the activity of the regulatory region within a non-diseased cell. This allows a better understanding of the diseased state to be studied.

The cell into which the adenoviral vector is inserted may be selected from normal cells, macrophages, dendritic cells, phagocytes, epithelium, endothelium, tissue or cell lines. Adenoviral vectors of the invention can be introduced into cells using the natural capability of

the viruses and centre cells and to mediate uptake of macromolecules, that is by receptor-mediator endocytosis. Alternatively, the vectors can be introduced by any other suitable means such as transfection, calcium phosphate-mediated transformation, microinjection, electroporation, osmotic shock and the like.

The invention also provides a mammalian cell, especially a human cell, containing an adenoviral vector according to the invention. The type of cell may be selected from those listed above.

The invention also relates to kits comprising vectors according to the invention. Such kits may also include instructions for the use of the vector.

The invention also provides a method of screening a compound as an enhancer or an inhibitor of a mammalian regulatory region, comprising the use of an adenoviral vector according to the invention. the vector may be placed into a suitable cell, and the effect of the compound on the amount of reporter gene product produced observed. Preferably, the compound may act directly on the regulatory region or indirectly via, for example, a cascade pathway.

Embodiments of the invention will now be described by way of example only with reference to the following figures and examples.

**Figure 1: Schematic representation of TNF reporter constructs.**

The TNF promoter lying before the 5'UTR of TNF is represented as a thin line. The 5' and 3'UTR are represented by hatched bars. The luciferase coding sequence is shown as a solid bar. Locations of the start codon, stop codon and TATA box are indicated for each construct. For the construct TNF promoter 5'UTR, SV40 poly(A) sequence is represented by an open bar. For the construct TNF promoter 5'3'UTR, the AU-rich element (ARE) sequences are indicated as a grey box. Both constructs are produced in vector pGL3 and pAdeasy1 for transfection and adenovirus infection experiments, respectively.



**Figure 2: Activity of TNF based reporter constructs when transfected or infected into RAW 264.7 and human macrophages.**

*A, B* - cells were either transfected (*A*) or infected with adenoviral constructs at m.o.i. 40:1 (*A, B*). Following LPS (10 ng/ml.) stimulation (4h), cells were then harvested and assayed for luciferase. *C, D* - Induction by LPS (10 ng/ml.) or Zymosan (30 µg/ml.) of luciferase activity (*C*) and TNF production (*D*), in Advp5' and Advp5'3'UTR infected human macrophages. Cells were stimulated for 4h before assay. In absence of stimuli, TNF production was undetectable. Each experiment was repeated at least three times.

**Figure 3: Comparison of the kinetics of LPS-induced TNF production and luciferase expression in human macrophages.**

Cells were either uninfected (*A*) or infected with Advp5' (*B*) or Advp5'3'UTR (*C*) and either untreated (*O*), or activated with 10 ng/ml. LPS (*●*). At the indicated times, cell lysates or culture supernatants were harvested to assay luciferase or TNF production respectively. In the absence of LPS, TNF production was undetectable. Figure 3(*D*) Cells were infected with Advp5' (*□*) or Advp5'3'UTR (*○*) and activated with LPS for four hours. Actinomycin D was added to stop any further mRNA synthesis and the cells incubated for a further 0, 15, 30, 45 or 60 minutes. after which time they were harvested for RPA analysis of luciferase or GAPDH mRNA. The results are shown normalised to 100% at the 0 minute point. Each experiment was repeated at least two (*D*) or three (*A-C*) times with blood from distinct donors.

**Figure 4: IL-10 inhibition of reporter gene constructs requires the 3'UTR.**

Cells were infected with Advp5' (*A*) or Advp5'3'UTR (*B*) and activated simultaneously with LPS (10 ng/ml.) and various concentrations of IL-10. Luciferase activities (*●*) and TNF production (*○*) were assayed after 4h LPS stimulation. Ordinates represent the percentages of luciferase activation and TNF production induced by LPS, in the absence of IL-10. Data are mean values ± S.E.M. from 4 separate experiments conducted with blood from different donors.

**Figure 5: Kinetics of IL-10 inhibitory activity on TNF production and luciferase expression.**

Human monocytes-derived macrophages were uninfected (A) or infected with Advp5'3'UTR (B), or Advp5' (C) (m.o.i. 40:1) and then incubated with LPS in the presence (○), or absence (●) of IL-10 (10 ng/ml.). The experiment was harvested at indicated times and TNF and luciferase assayed. Data are mean values ( $\pm$ ) from duplicates and are representative of three separate experiments conducted with distinct donors.

**Figure 6: Effect of IL-10 on TNF and Luciferase mRNA levels.**

Human macrophages infected with either Advp5', Advp5'3'UTR or Adv0 were treated with IL-10 (10 ng/ml.) simultaneously or 24h before LPS. Four hours after LPS activation, the experiment was harvested and ribonuclease protection assays were performed to quantify luciferase or TNF/GAPDH mRNA ratios. These are plotted as percentage of the maximum value in presence of LPS alone.

**Figure 7: IL-10 can inhibit TNF expression even when added post-LPS stimulation.**

Human macrophages infected with either Advp5' or Advp5'3'UTR (m.o.i. 40:1) were incubated for 4h in the presence of LPS (10 ng/ml.). IL-10 (10 ng/ml.) was added at the given times after LPS. Ordinates represent the percentages of luciferase activation and TNF production induced by LPS in the absence of IL-10. Data are mean values ( $\pm$ ) from duplicates and are representative of three separate experiments conducted with distinct donors.

**Figure 8: Effect of prolonged exposure to IL-10 prior to LPS stimulation on luciferase expression.**

Human macrophages infected with either Advp5' or Advp5'3'UTR were treated with IL-10 (10 ng/ml.) for the given times prior to LPS-stimulation. Four hours after LPS activation, the experiment was harvested and luciferase activities and TNF expression assayed. Data are mean values ( $\pm$ ) from duplicates and are representative of three separate experiments conducted with distinct donors.

**Figure 9: Prolonged exposure to IL-10 prior to LPS-stimulation results in the inhibition of luciferase expression in the absence of 3'UTR.**

Infected cells (Advp5' (A), Advp5'3'UTR (B) were pre-treated for 24h with various concentrations of IL-10 before LPS exposure. The experiment was harvested after 4h LPS stimulation and luciferase activities (●) and TNF production (○) were assayed. Data are expressed as percentages of luciferase activation and TNF production induced by LPS in absence of IL-10. Data are mean values ( $\pm$  SEM) from four experiments done with different donors.

**Figure 10: In murine cells, IL-10 inhibition of luciferase expression requires the 3'UTR regardless of length of exposure to the cytokine.**

Infected cells (m.o.i. 40:1) were incubated in presence of LPS (10 ng/ml.) without (■), or with IL-10 (10 ng/ml.) added simultaneously (□) or 24h before LPS addition (□). After LPS stimulation (4h), mTNF production and luciferase activities were assayed. Ordinates represent the percentages of luciferase activation and TNF production induced by LPS in the absence of cytokine. The results are representative of three (RAW264.7 cells) or two (primary murine macrophages) experiments.

## METHODS

### Plasmids

Human *TNF* promoter (-1173bp) with 3'untranslated region of the human *TNF* gene (pGL3-*TNF*-3'UTR) or without the 3' UT region (pGL3-*TNF*) (Udalova *et al.*, 1998) and the human *IL10* promoter construct (-4080bp) (pGL3-*IL10*) were subcloned into the pAdTrack vector (He *et al.*, 1998) to generate pAdTrack-*TNF*-Luc-3'UTR, pAdTrack-*TNR*-Luc and pAdTrack-*IL10*-Luc. For both later ones, KpnI/Sall fragments containing the human *TNF* or *IL10* promoter, the luciferase reporter gene and the SV40 late poly (A) signal were derived from their pGL3 respective constructs and cloned into KpnI/Sall sites of AdTrack vector.

The 3'UTR construct was obtained by substituting a XbaI/BamHI fragment containing the SV40 late poly(A) signal in the pGL3-*TNF* plasmid for approximately 1kbp of 3'UTR amplified by PCR with corresponding primers: 3'UTR-F (XbaI):

aattctagaGGAGGACGAACATCCAAC;

3'UTR-R(BamHI):

aatGgATcCCCAGAGTTGGAAATTC. The KpnI/Sall fragments were subsequently cloned into the pAdTrack vector.

### Adenoviral vectors and their propagation

The pAdEasy-1 adenoviral plasmid was provided by B. Vogelstein (The Howard Hughes Medical Institute, Baltimore, MD) and disclosed in He *et al.* Recombinant viruses were generated in BJ5183 bacterial cells transformed by the heat-shock method with 1µg of linearised modified AdTrack constructs and 100ng of replication-deficient adenoviral vector pAdEasy-1. Positive recombinant clones were selected through their resistance to kanamycin. Following selection DNA extracted was used for virus propagation in the 293 human embryonic kidney cells. Viruses were purified by ultracentrifugation through two cesium chloride gradients as described in He *et al.*, 1998. Titres of viral stocks were determined by plaque assay in 293 cells after exposure for 1 hour in serum free DMEM medium (Gibco BRL) and subsequently overlaid with 1.6% agarose/2xDMEM with 4% FCS mixture v/v1:1 and incubated for 10-14 days (He *et al.*, 1998).

## Cells

Mononuclear cells were isolated from single donor plateletpheresis residues by Ficoll-Hypaque centrifugation proceeding monocyte separation in a Beckman JE6 elutriator (High Wycombe, UK). Monocyte purity was assessed by flow cytometry with CD14 and was approx. 80% (Williams *et al.*, 1996).

The elutriated human monocytes were incubated at  $1 \times 10^6$ /ml in RPMI 1640 with 25 mM HEPES and 2 mM L-glutamine supplemented with 10% (v/v) heat-inactivated FBS and 10 U/ml penicillin/streptavidin. To optimize infection, purified human monocytes were pretreated with M-CSF at 100ng/ml (Genetics Institute, Boston, MA) for 48h to allow up-regulation of integrin  $\alpha_v\beta_3$ , which has previously been shown to be essential for adenovirus infection of monocytes (Huang *et al.*, 1995).

RAW 264.7 mouse macrophages were maintained in DMEM supplemented with 10% FCS and 10 U/ml penicillin/streptavidin.

## Transfection and Infection

$0.5 \times 10^6$  RAW 264.7 cells/well were plated in growth medium (6 wells/plate). The following day, cells were transfected with 100 ng of DNA by using Superfect (Qiagen, Germany). For infection, these cells were plated at  $0.1 \times 10^6$ /well (48 wells/plate). After M-CSF treatment human macrophages were replated at  $0.2 \times 10^6$ /well (96 wells/plate). RAW 264.7 and M-CSF treated macrophages were then exposed to virus for 1h in serum free medium followed by washing and reculturing in growth medium with 2% FCS for 24h. For Adv *TNF*-Luc and Adv *TNF*-Luc-3'UTR, RAW 264.7 and M-CSF-treated macrophages were infected with a multiplicity of infection (MOI) of 40:1. Infected or transfected cells were then stimulated with LPS (10 ng/ml) for 4h. Infection of M-CSF treated macrophages by Adv *IL10*-Luc was efficient at MOI of 80:1 and cells were stimulated for 18h with LPS (*Salmonella typhimorium*, Sigma, Poole, UK.).

**Luciferase assay**

After LPS stimulation, cells were washed once in PBS and lysed with 100 µl of CAT lysis buffer (0.65% (v/v) of NP40, 10 mM of Tris-HCL pH 8, 0.1 mM EDTA pH8, 150 mM NaCl). 50 µl of cell lysate was transferred into the well of a luminometer cuvette strip and Luciferase Assay Buffer (220 µl) added. Luciferase activity was measured with a Labsystem luminometer by dispensing 30 µl luciferin (1.5 mM, Sigma) per assay point.

**Measurement of hTNF and mTNF production.**

TNF levels were measured in cell supernatants by sandwich enzyme-linked immunosorbent assay (ELISA). A polyclonal rabbit anti-mouse TNF antibody for coating and the same biotinylated polyclonal antibody were used to detect mTNF. ELISA for hTNF was performed as previously reported (Engelberts, I., *et al.* 1991, *Lymphokine Cytokine Res.* 1-2, 69).

**Ribonuclease protection assay (RPA).**

After M-CSF treatment, cells were plated at  $2 \times 10^6$ /w in 12-well plate and infected as described above. In Advp5' and Advp5'3'UTR infected cells Luciferase and GAPDH mRNAs were detected by ribonuclease protection assay by using luciferase and GAPDH riboprobes, respectively. In parallel, TNF and GAPDH mRNAs were detected in Adv0-infected cells. Riboprobe vectors were constructed as follows. A 352-bp *HincII-XbaI* luciferase fragment was cloned from pGL3c (Promega) into pBluescript KS that had been digested with *EcoRV* and *XbaI*. A 268-bp TNF gene fragment was amplified by PCR from human genomic DNA, and subcloned into *SpeI* site of pBluescript KS<sup>+</sup> (kindly provided by Dr A Clark, Kennedy Institute, London, UK.) that had been digested with *SpeI*. Riboprobe template constructs were linearized by appropriate restriction and purified by phenol-chloroform extraction and ethanol precipitation. Luciferase and GAPDH riboprobes were synthesized using T7 polymerase and TNF riboprobe by using T3 polymerase (Boehringer Mannheim) in the presence of 50 µCi of [ $\alpha$ -<sup>32</sup>P]UTP (800 mCi/mmol; Amersham). The final concentration of unlabelled UTP in *in vitro* transcription reactions was 12 µM, except in the case of Luciferase where it was 2.4 µM. Ribonuclease protection assays were carried out using the Direct

Protect kit (Ambion). Under the conditions of hybridization DNA-RNA heteroduplexes were not detected. Protected RNA fragments were resolved by electrophoresis on denaturing 6% polyacrylamide gels and were visualized and quantified by phosphorimaging (Fuji FLA 2000) and autoradiography. Each experiment was performed twice, and serial dilutions of lysates were used to check that quantitations were within the linear range of the assay.

## RESULTS

### **Comparison of TNF reporter gene activity when delivered by adenoviral infection as opposed to standard DNA transfection.**

The TNF gene reporter constructs used in this study are schematically illustrated in Figure 1. The 5'promoter and 5'promoter-3'UTR constructs, were incorporated into the pGL3 vector for transient transfection experiments (using Lipofectin), or recombinant adenoviruses (reporter viruses, Advp5' and Advp5'3'UTR respectively) for infection studies. Initial studies compared the response of the reporter gene to LPS when delivered by transfection, with infection. The RAW 264.7 murine macrophage cell line was used for these studies, as our attempts to transfect primary human monocytes or macrophages have proved unsuccessful. Lipofection was the transfection method of choice as, in our hands, this had been found to be the most efficient for the RAW 264.7 cells (results not shown). LPS stimulation of transfected cells gave a modest absolute signal and resulted in an approximate 20-fold response by both 5' and 5'3' constructs. This level of response was not dissimilar to other reported studies with the same type of construct and technique in this cell line (Hacker *et al.* (1999) *Embo J.* 24, 6973). For comparison, both RAW 264.7 cells and primary human macrophages were infected with virus at m.o.i. 40:1, as previous studies had indicated that this concentration resulted in the successful infection of >90% of cells ((13, data not shown). In contrast to the transfection study, RAW 264.7 cells, infected with reporter adenovirus, gave LPS responses of 60-70 fold and much higher absolute values of luciferase activity (Figure 2A). LPS activation of the reporter gene in human macrophages infected with the reporter viruses resulted in 166 and 115 fold stimulation of the 5' and 5'3'UTR constructs respectively (Figure 2B). The strength of response varied from donor to donor and it has not been uncommon to obtain activations in excess of 250 fold. The greater response of human compared to murine cells has been a consistent finding. One possible reason for this is that the reporter gene constructs are based on the human sequence. The reporter gene also responded equally well to the yeast product, zymosan, an alternative stimulus of TNF production with a similar potency to LPS (Figure 2C, 2D). A consistent finding in all systems, regardless of the means of gene delivery or stimulus, was the lower absolute response of constructs containing the 3'UTR. These data would support the view, obtained



from previous studies only in murine macrophage cell lines, that the 3'UTR is generally suppressive to TNF expression (Han (1991) *J. Immunol.* 6, 1843). The powerful inducible response of the TNF gene is its notable characteristic. Therefore, it was interesting to find that the virally delivered reporter gene gave responses (activation in excess of 100 fold) that are much more comparable to the endogenous TNF gene than the transfected constructs (activation of 10 fold).

### Infection

Cell type	Virus	Luciferase activity		Fold activation
		No LPS	With LPS	
RAW 264.7	Adv <i>TNF</i> -Luc	3 ± 2	216 ± 206	75 ± 34 (N=6)
	Adv <i>TNF</i> -Luc -3'UTR	0.8 ± 0.3	49 ± 60	51 ± 47 (N=6)
M-CSF treated human macrophage	Adv <i>TNF</i> -Luc	30 ± 26	4241 ± 1869	252 ± 165 (n=8)
	Adv <i>TNF</i> -Luc-3'UTR	7.5 ± 8.7	1008 ± 660	150 ± 86 (n=8)
	Adv <i>IL10</i> -Luc	1.8 ± 2	220 ± 96	159 ± 100 (n=5)

### Transfection

Cell type	DNA	Luciferase activity		Fold activation
		No LPS	With LPS	
RAW 264.7	pGL3- <i>TNF</i>	2 ± 1	19 ± 7	10 ± 1 (n≥3)
	pGL3- <i>TNF</i> -3'UTR	0.17	2.5	15 (n≥3)

Kinetic studies were also performed to compare the behaviour of the reporter genes with the endogenous gene in human macrophages. In response to LPS, TNF production reached a maximum four hours after stimulation and thereafter, decreased slowly with a half-life of approximately 18.5 hours (Figure 3A). The kinetics of luciferase activity from Advp5' or Advp5'3'UTR infected LPS-stimulated human macrophages followed a similar profile to TNF, with maximum expression at 4 hours and apparent half-lives estimated to be 23.5 and 12 hours respectively (Figure 3B, 3C). The shorter half-life of luciferase, when under the addition control of the 3'UTR, might be expected from the overall destabilising effect of this element on TNF mRNA (Hacker, Supra; Kruys, *et al.* (1993) *J. Exp. Med.* 5, 1383). To confirm this, studies on luciferase mRNA stability were performed that showed the presence

of the 3'UTR does indeed increase the rate of decay of luciferase mRNA (Figure 3D). In the presence of the 3'UTR the mRNA had a half life of 56 minutes, however, in the absence of this element, there was little decay (<15%) within the same time frame. One might have expected that the half-life of the endogenous TNF protein would have been comparable to the 5'3'UTR rather than the 5' construct. However, these data do not take into account potential differences in the biological half-lives of the TNF and luciferase proteins and one can only assume that the half-life of the endogenous TNF would be longer in the absence of the 3'UTR in humans, as shown previously in mouse cells with deletions of the 3'UTR on the AU-rich region of the 3'UTR.

**In primary human macrophages, IL-10 requires the 3'UTR to inhibit TNF production.**

The effectiveness of adenovirus delivery of TNF-based reporter gene constructs to primary human macrophages led us to investigate what role the 5' and 3' regions may play in the IL-10 inhibition of TNF expression. Adeno-reporter virus-infected cells were simultaneously treated with LPS and various concentrations of IL-10 for 4 hours, after which TNF production and luciferase activities were assayed (Figure 4). IL-10 inhibited TNF expression to a maximum of 80% at 10 ng/ml. (Figure 4A, 4B). However, the response of the two reporter constructs was quite distinct. The 5' construct was only weakly inhibited by IL-10, approximately 10%, whereas the 5'3'UTR construct showed a dose response profile similar to the endogenous TNF, although the maximum inhibition attained was less, 60% at 10 ng/ml. The  $IC_{50}$  for IL-10 on TNF protein was 0.2-0.3 ng/ml., compared with 2-3 ng/ml. for the reporter gene. However, if the concentration of half-maximal inhibition is calculated, then the activity of IL-10 is similar for the endogenous gene (~0.1 ng/ml.) and the 5'3'UTR construct (0.2-0.3 ng/ml.). This suggests that aspects of the inhibitory activity of IL-10 on the reporter gene and the endogenous gene are similar. The kinetics of the IL-10 inhibition of TNF and luciferase expression was also compared using the optimal concentration of 10 ng/ml. (Figure 5). Over the two to twenty-four hour period post-stimulation, the expression of TNF and the 5'3'UTR construct gave very similar profiles with very little response detected in the presence of IL-10 (Figure 5A, 5B). The effect of IL-10 on the 5' construct was, again, much weaker, with no significant inhibition over the time course (Figure 5C). These data would suggest that the major inhibitory effect of IL-10 is mediated via the 3'UTR and that

there appears to be little effect on the transcription of the gene when IL-10 is administered at the same time as LPS. To gain a further insight into the mechanism of IL-10 activity, luciferase mRNA levels were analysed by RPA. As shown in Figure 6, simultaneous IL-10 addition caused a marked reduction of luciferase mRNA from the 5'3'UTR construct, whereas, there was only a marginal effect on mRNA from the 5' construct. These data indicates that IL-10 causes a potential destabilization/enhanced destruction of mRNA via the 3'UTR. Data obtained with TNF mRNA showed identical results to the 5'3'UTR construct (Figure 6).

The data so far indicates that IL-10 mediates its activity on the post-transcriptional mechanism associated with TNF production. If this is so, IL-10 should still be able to inhibit TNF production, at least for a period, if added after LPS. Reporter virus infected macrophages were stimulated with LPS and IL-10 was added for periods of up to 2 hours post-activation; as before the experiment was harvested at 4 hours for assay. As expected, IL-10 had little effect on the activity of the 5' construct, regardless of when it was added (Figure 7). The inhibitory effect of IL-10 on TNF and the expression of the 5'3'UTR construct was maintained, even if IL-10 was added 1 hour after LPS activation but was greatly reduced if the cytokine was added 2 hours post-activation (Figure 7). These data would suggest that IL-10 does not inhibit the early events that are involved in TNF production (e.g. transcription) and instead, targets later events (e.g. post-transcriptional). This agrees with the hypothesis that post-transcriptional control mediated via the 3'UTR is the target of IL-10.

**Pre-incubation of human macrophages with IL-10 before LPS stimulation reveals a second mechanism of inhibiting TNF production through the 5' promoter.**

As time of exposure to IL-10 could obviously have a bearing on its function, this study was extended to investigate the effect of adding IL-10 before LPS for periods up to 24 hours (Figure 8). Pre-incubating macrophages with IL-10 for 12 hours produced a modest increase in the inhibition of endogenous TNF production or luciferase activity from the 5'3'UTR reporter gene when compared with the effect of simultaneous addition of LPS and IL-10 (Figure 8). Further periods of pre-incubation up to 24 hours did not elicit any major

additional effect. However, pre-exposure of cells to IL-10 had a profound effect on the expression of the 5' reporter. Pre-incubation of macrophages with IL-10 for twelve hours before LPS stimulus resulted in 50% inhibition of the 5' construct that increased to nearly 70% when the pre-incubation period was extended to 24 hours (Figure 8). This was compared to the 80% inhibition of endogenous TNF production. The effect of pre-incubating macrophages for 24 hours with different concentrations of IL-10 was also examined. As shown in Figure 9, LPS-induced TNF protein expression was inhibited to a maximum of 90% (10 ng/ml. IL-10) with an IC<sub>50</sub> of ~0.1 ng/ml. regardless of which reporter construct had been infected into the macrophages. IL-10 also inhibited the expression of the 5'3'UTR reporter to an identical degree to the endogenous gene (Figure 9B). However, in contrast to data in Figure 4A, pre-incubation for 24 hours with IL-10 now produced a dose-dependent inhibition of the 5'UTR construct that showed a maximum inhibition of 60% at 10 ng/ml. (Figure 9A). The IC<sub>50</sub> for IL-10 on the 5' construct was 5 ng/ml. but this reduced to 0.5 ng/ml. if the half-maximal inhibition was again calculated. These data would indicate that in addition to post-transcriptional regulation of the TNF gene, IL-10 can also inhibit transcription of the TNF gene if cells are exposed to this inhibitory factor for a sufficient period. Indeed, studies on mRNA levels showed that pre-incubation, for 24 hours, with IL-10 resulted in a decrease in luciferase mRNA regardless of the presence of the 3'UTR (Figure 6).

**IL-10 cannot inhibit TNF gene by the 5' promoter in primary murine macrophages and cell lines.**

To the inventors' knowledge, the potential dual mechanism of IL-10 inhibitory activity on TNF expression has not been previously described. However, the type of reporter gene study described here is also novel. We therefore applied the adeno-reporter virus approach to murine macrophage cell lines and murine peritoneal derived macrophages systems that are more commonly used to investigate IL-10 function. We have previously shown that the murine macrophage cell line RAW 264.7 would be infected by adenovirus (Figure 2), and we have found that murine peritoneal derived macrophages were also permissive to virus infection (results not shown). We observed that a m.o.i. 40 of adenovirus was sufficient to infect murine primary cells and that LPS would activate both the 5' and 5'3'UTR constructs

(results not shown). Murine cells were infected with reporter viruses and were either pre-incubated with IL-10 for 24 hours or given the cytokine simultaneously with LPS (Figure 10). We had previously ascertained that 10 ng/ml. IL-10 was an optimal concentration for the inhibition of TNF production by the murine cells (23). For simplicity the data with IL-10 from each study are shown as a comparison with the LPS only control that is given as 100% (Figure 10). In RAW 264.7 cells, IL-10 inhibited TNF production and 5'3' luciferase construct to a similar degree when added with LPS. However, there was no inhibition of the 5' construct even when RAW 264.7 cells were pre-incubated with IL-10. Also, pre-exposure to the cytokine reduced the inhibition of luciferase expression by the 5'3' construct although the inhibition of endogenous TNF was maintained. The study was repeated on primary murine macrophages since RAW 264.7 are transformed and this could affect the mechanisms of IL-10 action. IL-10 produced a profound inhibition of TNF production by primary murine macrophages regardless of length of treatment with cytokine. However, the effect on the expression of 5'3'UTR was only moderate, achieving a 30% inhibition. Again, this was not affected by pre-incubation with IL-10. There was no effect on the expression of the 5' construct under any of these circumstances. A trivial reason for the failure to demonstrate any effect on 5' construct, at least on the murine cells, was that these studies were performed with human rather than murine IL-10. However, repetition of these studies with the murine IL-10 gave similar results (results not shown).

**DISCUSSION**

The results show that viral transfer allows improved reporter gene induction (60 to 80 fold) in cell lines and even more so in primary cells (approximately 200 fold) following LPS stimulation. This result is unexpected and demonstrates that use of an adenoviral construct has unexpected advantages over the prior art.

The constructs have also been demonstrated to be able to be used to study regulatory region, such as cytokine, activity with primary macrophages which has previously been difficult to undertake.

**REFERENCES**

Udalova, I.A., Knight, J.C., Vidal, V., Nedospasov, S.A. & Kwiatkowski, D. Complex NF-kappaB interactions at the distal tumor necrosis factor promoter region in human monocytes. *J Biol Chem* **273**, 21178-86 (1998).

He, T.C., *et al.* A simplified system for generating recombinant adenoviruses, *Proc Natl Acad Sci USA* **95**, 2509-14 (1998).

Huang S., *J. Virol.*, **69**(4), 2257-63 (1995).

Williams, L.M., Gibbons, D.L., Gearing, A., Maini, R.N., Feldmann, M. & Brennan, F.M. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF $\alpha$  processing in RA synovial membrane cell cultures. *J Clin Invest* **97**, 2833-41 (1996).

## ANNEX 1

LOCUS (LOC): HUMTNFAB GenBank (R)  
 GenBank ACC. NO. (GBN): M16441  
 CAS REGISTRY NO. (RN): 140752-05-2  
 SEQUENCE LENGTH (SQL): 7112  
 MOLECULE TYPE (CI): DNA; linear  
 DIVISION CODE (CI): Primates  
 DATE (DATE): 14 Jan 1995  
 DEFINITION (DEF): Human tumor necrosis factor and lymphotoxin  
 genes, complete cds.  
 KEYWORDS (ST): lymphotoxin; tumor necrosis factor  
 SOURCE: Human placenta DNA, clone pTNF186.  
 ORGANISM (ORGN): Homo sapiens  
 Eukaryotae; mitochondrial eukaryotes; Metazoa;  
 Chordata; Vertebrata; Eutheria; Primates;  
 Catarrhini; Hominidae; Homo  
 NUCLEIC ACID COUNT (NA): 1676 a 2005 c 1865 g 1566 t  
 ORIGIN: 1 bp upstream of EcoRI site; chromosome 6p21.3.  
 COMMENT: Draft entry and computer-readable sequence for [1]  
 kindly submitted by C.V.Jongeneel, 02-OCT-1988.  
 REFERENCE: 1 (bases 1 to 7112)  
 AUTHOR (AU): Nedospasov,S.A.; Shakhov,A.N.; Turetskaya,R.L.;  
 Mett,V.A.; Azizov,M.M.; Georgiev,G.P.; Korobko,  
 V.G.; Dobrynin,V.N.; Filippov,S.A.; Bystrov,N.S.;  
 Boldyreva,E.F.; Chuvpilo,S.A.; Chumakov,A.M.;  
 Shingarova,L.N.; Ovchinnikov,Y.A.  
 TITLE (TI): Tandem arrangement of genes coding for tumor  
 necrosis factor (TNF-alpha) and lymphotoxin  
 (TNF-beta) in the human genome  
 JOURNAL (SO): Cold Spring Harb. Symp. Quant. Biol., 51 Pt 1,  
 611-624 (1986)  
 OTHER SOURCE (OS): CA 107:110246

## FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..7112	/organism="Homo sapiens"
prim-transcript	819..2855	/map="6p21.3"
intron	980..1266	/note="lymphotoxin mRNA and introns"
CDS	join(1276..1374, 1461..1566,1814..2226)	/note="lymphotoxin intron A" /note="lymphotoxin"
		/codon-start=1
		/db-xref="PID:g339740"
		/translation="MTPPERLFLPRVCGTTLHLL LLGILLVLLPGAQGLPGVGLTPSA AQTARQHFKMHLAHS TLKPA AHLIGDPSKQNSLL WRANTDRAFLQDGFSLSNNSLLVP TSGIYFVYSQVVFSGKAYSPKATSSPLYLAHEVQ



gene 1276..1374  
 exon <1276..1374

intron 1375..1460  
 exon 1461..1566  
 intron 1567..1813  
 exon 1814..>2226

prim-transcript 4095..6859  
 exon <4275..4460

gene 4275..4460  
 CDS join(4275..4460,  
 5067..5112,5300..5347,  
 5649..6070)

intron 4461..5066  
 exon 5067..5112  
 intron 5113..5299  
 exon 5300..5347  
 intron 5348..5648

LFSSQYPFHVPLLSSQKMVYPGLQ  
 EPWLHSMYHGAAFQLTQGDQLSTHTDGIPHLVLS  
 PSTVFFGAFAL"

/gene="TNFB"  
 /gene="TNFB"  
 /note="lymphotoxin, (first  
 expressed exon); G00-120-442"  
 /number=2

/note="lymphotoxin intron B"  
 /number=3  
 /note="lymphotoxin intron C"  
 /note="lymphotoxin"  
 /number=4

/note="TNF mRNA and introns"  
 /gene="TNFA"  
 /note="tumor necrosis factor;  
 G00-120-441"  
 /number=1

/gene="TNFA"  
 /note="tumor necrosis factor"

/codon-start=1  
 /db-xref="PID:g339741"  
 /translation="MSTESMIRDVELAEALPKK  
 TGGPQGSRRCLFLSLFSFLIVAGA  
 TTLFCLLHFGVIGPQREEFPRDLISLISPLAQA  
 VRRSSSRTPSDKPVAVHVVANPQAEQQL  
 QWLNRRANALLANGVELRDNQLVVPSEGLYLIYS  
 QVLFKGQCCPSTHVLLTHTISRIA  
 VSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPI  
 YLGGVFQLEKGDRLSAEINRPDYL  
 DFAESGQVYFGIIAL"

/note="TNF intron A"

/note="TNF intron B"

/number=3

/note="TNF intron C"

#### SEQUENCE (SEQ):

```

1  gaattctcga aacttccttt gtagaaaact ttggaaggtg tctgccacat tgatcctgga
61 atgtgtgttt atttgggggt atataaatct gttctgtgga agccacctga agtcagggaag
121 agatggaggg catccttcag gtagtgagatg agacctcatc atacttgact gtccagcatc
181 atctctgagt gaggggacca aaaaatttat cttccaaact aggacacttt caagagtggga
241 aggggggatcc attaatatth tcacctggac aagaggcaaa caccagaatg tccccgatga
301 aggggatata taatggacct tcttgatgtg aaacctgcca gatgggctgg aaagtccgta
361 tactgggaca agtatgattt gagttgtttg ggacaaggac aggggtacaa gagaaggaaa
421 tgggcaaaga gagaagcctg tactcagcca aggggtgcaga gatgttatat atgattgctc
481 ttcagggaac cgggcctcca gctcacaccc cagctgctca accacctcct ctctgaattg
541 actgtccctt ctttggaact ctaggcctga cccactccc tggeccctccc agcccacgat
601 tcccctgacc cgactccctt tcccagaact cagtcgcctg aacccccagc ctgtggttct
661 ctccctaggcc tcagccctttc ctgccccttg ctgaaacagc agtatcttct aagccctggg
721 ggcttccccg ggccccagcc ccgacctaga acccgcccgc tgccctgccac gctgccactg
781 ccgcttccctc tataaaggga cctgagcgct cgggcccagg ggctccgcac agcagggtgag
841 gctctcctgc cccatctcct tgggctgccc gtgcttcctg ctttgacta ccgcccagca
901 gtgtcctgcc ctctgcctgg gcctcggtcc ctcctgcacc tgetgcctgg atccccggcc
961 tgccctgggccc tgggccttgg tgggttttgt tttggtttcc ttctctgtct ctgactctcc
1021 atctgtcagt ctcatgtct ctgtcacaca ttctctgttt ctgccatgat tctctctgtt
1081 tcccttccctg tctctctctg tctccctctg ctacacttgg ggtttctctg actgcatctt
1141 gtcccccttct ctgtcgatct ctctctcggg ggctcggggg tgctgtctcc cagggcgggg
1201 ggtctgtctt ccgcccgggt ccccgccccg ctactgtct ctctctctct ctctcttctt
1261 ctgcagggtt tccccatgac accacctgaa cgtctcttcc tcccagggtg gtgtggcacc

```

1321 accctacacc tcctccttct ggggctgctg ctggttctgc tgcctggggc ccagggtgagg  
1381 cagcaggaga atgggggctg ctggggtggc tcagccaaac cttgagccct agagccccc  
1441 tcaactctgt tctcccctag gggctccctg gtgttggcct cacaccttca gctgcccaga  
1501 ctgcccgtca gcaccccaag atgcatcttg cccacagcac cctcaaacct gctgctcacc  
1561 tcattggtaa acatccacct gacctcccag acatgtcccc accagctctc ctccctacccc  
1621 tgcctcagga acccaagcat ccacccctct cccccaactt ccccccagct aaaaaaaca  
1681 gagggagccc actcctatgc ctccccctgc catccccag gaactcagtt gttcagtgcc  
1741 cacttcctca gggattgaga cctctgatcc agacccctga tctcccaccc ccctccccta  
1801 tggctcttcc taggagaccc cagcaagcag aactcactgc tctggagagc aaacacggac  
1861 cgtgccttcc tccaggatgg tttctccttg agcaacaatt ctctcctggc cccaccaggt  
1921 ggcactctact tctgtactc ccagggtggc ttctctggga aagcctactc tccaagggcc  
1981 acctcctccc cactctacct ggcccatgag gtccagctct tctcctccca gtaccccttc  
2041 catgtgcctc tcctcagctc ccagaagatg gtgtatccag ggctgcagga accctggctg  
2101 gagggagccc accacggggc tgcgttccag ctcaccagg gagaccagtt atccaccac  
2161 acagatggca tccccacct agtccctcag cctagtactg tcttctttgg tcttctgct  
2221 ctgtagaact tggaaaaatc cagaaagaaa aaataattga tttcaagacc ttctcccat  
2281 tctgcctcca ttctgacct ttcagggggc gtcaccacct ctcttttggc cattccaaca  
2341 gctcaagtct tccctgatca agtcaccgga gctttcaaag aaggaaattct aggcattcca  
2401 ggggaccaca cctccctgaa ccatccctga tgtctgtctg gctgaggatt tcaagcctgc  
2461 ctaggaattc ccagcccaaa gctgttggc ttgtccacca gctaggtggg gcctagatcc  
2521 acacacagag gaagacagag cacatggagg agcttggggg atgactagag gcagggaggg  
2581 gactatttat gaaggcaaaa aaattaaatt atttatttat ggaggatgga gagagggga  
2641 taatagaaga acatccaagg agaaacagag acaggcccaa gagatgaaga gtgagaggcc  
2701 atgcgacaaa ggctgaccaa gagagaaaga agtaggcacg agggatcaca gggcccaga  
2761 aggcagggaa aggtcttgaa agccagctgc cgaccagagc cccacacgga ggcactctga  
2821 ccctcgatga agcccaataa acctcttttc tctgaaatgc tgtctgcttg tgtgtgtgtg  
2881 tctgggagtg agaacttccc agtctatcta aggaatggag ggagggacag agggctcaaa  
2941 catgacaaaa gctgtgggga gaacaaaagg ataagggtc agagagcttc agggatatgt  
3001 gatggactca ccagggtagg ccgcccagact gctgcagggg aagcaaaagg gaagctgga  
3061 agatgaagga aaagtacagg tctggagggg cgggggtcag ggagctcctg ggagatatgg  
3121 ccacatgtag cggctctgag gaatgggtta caggagacct ctggggagat gtgaccacag  
3181 caatgggtag gagaatgtcc agggctatga aagtctgagta tggggacccc ccttaacga  
3241 agacaggggc atgtagaggg cccaggggag tgaagagcc tccaggacct ccaggtatgg  
3301 aatacagggg acgtttaaga agatatggcc acacactggg gccctgagaa gtgagagctt  
3361 catgacaaaa atcaggggacc ccagagtcc ttggaagcca agactgaaac cagcattatg  
3421 agtctccggg tcagaatgaa agaagaggcc ctgccccagt ggggtctgtg aattccggg  
3481 ggtgatttca ctcccgggg ctgtcccagg cttgtccctg ctaccgcac ccagccttc  
3541 ctgaggcctc aagcctgcca ccaagccccc agctccttct ccccgaggg cccaaacaca  
3601 ggcctcagga ctcaacacag cttttccctc caaccccggt ttctctccct caacggactc  
3661 agctttctga agccctccc agttctagtt ctatcttttt cctgcatcct gtctggaagt  
3721 tagaaggaaa cagaccacag acctggtccc caaaagaaat ggaggcaata ggttttgagg  
3781 ggcagtgagg cggggttcag cctccagggg cctacacaca aatcagtcag tggcccagaa  
3841 gacccccctc ggaatcgag cagggaggat ggggagtggt aggggtatcc ttgatgcttg  
3901 tgtgtcccca actttccaaa tccccgcccc cgcatggag aagaaaccga gacagaaggt  
3961 gcaggggcca ctaccgcttc ctccagatga gctcatgggt ttctccacca aggaagtttt  
4021 ccgctggttg aatgattctt tccccgccct cctctcgccc cagggacata taaaggcagt  
4081 tgttggcaca cccagccagc agacgtccc tcagcaagga cagcagagga ccagctaaga  
4141 gggagagaag caactacaga cccccctga aaacaacct cagacgccac atccctgac  
4201 aagctgccag gcaggttctc ttctctcac atactgacc acggcttcac cctctctccc  
4261 ctggaaagga caccatgagc actgaaagca tgatccggga cgtggagctg gccgaggag  
4321 cgctcccaaa gaagacaggg gggccccagg gctccaggcg gtgcttgttc ctcagcctct  
4381 tctccttctt gatcgtggca ggcgccacca cgctctcttg cctgctgcac tttggagtga  
4441 tgggccccca gaggaagag gtgagtgcct ggccagcctt catccactct cccaccaag  
4501 gggaaatgga gacgcaagag agggagagag atgggatggg tgaaagatgt gcgctgatg  
4561 ggagggatgg agagaaaaa acgtggagaa agacggggat gcagaaagag atgtggcaag  
4621 agatggggaa gagagagaga gaaagatgga gagacaggat gtctggcaca tggaaggtgc  
4681 tactaagtgt tgtatggagt gaatgaatga atgaatgaat ggaagaaac aagtgatag  
4741 aagatatgga gacagatgtg ggggtgtgaga agagagatgg ggaagaaac aagtgatag  
4801 aataaagatg gtgagacaga aagagcggga aatatgacag ctaaggagag agatggggga  
4861 gataaggaga gaagaagata ggggtgtctg cacacagaag aactcaggg aaagagctgt  
4921 tgaatgcctg gaaggtgaat acacagatga atggagagag aaaaccagac acctcagggc  
4981 taagagcgca ggccagacag gcagccagct gttcctcctt taagggtgac tccctcgatg

5041 ttaaccatto tccttctccc caacagttcc ccagggacct ctctctaate agccctctgg  
5101 cccaggcagt cagtaagtgt ctccaaacct ctttccctaat tctgggtttg ggtttggggg  
5161 tagggtagt accggtatgg aagcagtggg ggaaatttaa agttttgggc ttgggggagg  
5221 atggatggag gtgaaagtag gggggtatct tctaggaagt ttaagggtct cagctttttc  
5281 ttttctctct cctcttcagg atcatcttct cgaaccccca gtgacaagcc tgtagcccat  
5341 gttgtaggta agagctctga ggatgtgtct tggaaacttg agggctagga tttggggatt  
5401 gaagcccggc tgatggtagg cagaacttgg agacaatgtg agaaggactc gctgagctca  
5461 aggggaaggt ggaggaacag cacaggcctt agtgggatac tcagaacgtc atggccagggt  
5521 gggatgtggg atgacagaca gagaggacag gaaccggatg tggggtgggc agagctcgag  
5581 ggccaggatg tggagagtga accgacatgg ccacactgac tctctctccc ctctctccct  
5641 ccctccagca aaccctcaag ctgaggggca gctccagtgg ctgaaccgcc gggccaatgc  
5701 cctcctggcc aatggcgtgg agctgagaga taaccagctg gtggtgccat cagagggcct  
5761 gtacctcacc tactcccagg tcctcttcaa gggccaaggt cgcctaccag accaagggtc acctcctctc  
5821 cctcaccacc accatcagcc gcctgcctgt cccagagggg gctgaggcca agccctggta  
5881 tgccatcaag agcccctgcc agagggtgac cccagagggg gctgaggcca agccctggta  
5941 tgagcccacc tatctgggag gggctctcca gctggagaag ggtgaccgac tcagcgtga  
6001 gatcaatcgg cccgactatc tcgactttgc cgagtctggg cagggtctact ttgggatcat  
6061 tgccctgtga ggaggacgaa catccaacct tcccaaaccg ctcccctgcc ccaatccctt  
6121 tattaccccc tccttcagac accctcaacc tcttctggct caaaaagaga attgggggct  
6181 tagggctcga acccaagctt agaactttaa gcaacaagac caccacttcg aaacctggga  
6241 ttcaggaatg tgtggcctgc acagtgaagt gctggcaacc actaagaatt caaactgggg  
6301 cctccagaac tctctggggc ctacagcttt gatccctgac atctggaatc tggagaccag  
6361 ggagcctttg gttctggcca gaatgctgca ggacttgaga agacctcacc tagaaattga  
6421 cacaagtgga ccttaggcct tcctctctcc agatgtttcc agacttcctt gagacacgga  
6481 gcccagccct ccccatggag ccagctccct ctatttatgt ttgcacttgt gattatttat  
6541 tattttattt ttattttatt atttacagat gaatgtattt atttgggaga ccggggtatc  
6601 ctggggggacc caatgtagga gctgccttgg ctccagacatg ttttccgtga aaacggagct  
6661 gaacaatagg ctgttcccat gtagcccccct ggcctctgtg ccttcttttg attatgtttt  
6721 ttaaaatatt tatctgatta agttgtctaa acaatgctga tttggtgacc aactgtcact  
6781 cattgctgag cctctgctcc ccaggggagt tgtgtctgta atcgccctac tattcagtgg  
6841 cgagaaataa agtttgctta gaaaagaaac atggtctcct tcttgggaatt aattctgcat  
6901 ctgcctcttc ttgtgggtgg gaagaagctc cctaagtcct ctctccacag gctttaagat  
6961 ccctcggacc cagtcccatc cttagactcc tagggccctg gagaccctac ataaacaaag  
7021 cccaacagaa tattcccatc cccccaggaa acaagagcct gaacctaat acctctccct  
7081 cagggcatgg gaatttccaa ctctgggaat tc

## ANNEX 2

GENBANK. RTM. COPYRIGHT 1999

LOCUS (LOC): HSINTL10 GenBank (R)  
GenBank ACC. NO. (GBN): \*\*\*X78437\*\*\*  
CAS REGISTRY NO. (RN): 156795-75-4  
SEQUENCE LENGTH (SQL): 4181  
MOLECULE TYPE (CI): DNA; linear  
DIVISION CODE (CI): Primates  
DATE (DATE): 27 Jan 1997  
DEFINITION (DEF): H.sapiens IL-10 gene.  
KEYWORDS (ST): IL-10 gene; interleukin 10  
SOURCE: human.  
ORGANISM (ORGN): Homo sapiens  
Eukaryotae; mitochondrial eukaryotes; Metazoa;  
Chordata; Vertebrata; Eutheria; Primates;  
Catarrhini;  
Hominidae; Homo  
NUCLEIC ACID COUNT (NA): 1181 a 1046 c 961 g 993 t  
REFERENCE: 1 (bases 1 to 4181)  
AUTHOR (AU): Kube,D.; Platzer,C.; von Knethen,A.; Straub,H.;  
Bohlen,H.; Hafner,M.; Tesch,H.  
TITLE (TI): Isolation of the human interleukin 10 promoter.  
Characterization of the promoter activity in  
Burkitt's  
lymphoma cell lines  
JOURNAL (SO): Cytokine, 7 (1), 1-7 (1995)  
OTHER SOURCE (OS): CA 122:125051  
REFERENCE: 2 (bases 1 to 4181)  
AUTHOR (AU): Kube,D.  
TITLE (TI): Direct Submission  
JOURNAL (SO): Submitted (21-MAR-1994) D. Kube, Medizinische  
Klinik I  
der Universitaet zu Koeln, LFI Ebene 4 Raum 508,  
Joseph-Stelzmann-Str 9, 50924 Koeln, FRG  
REFERENCE: 3 (bases 1 to 4181)  
AUTHOR (AU): Kube,D.  
TITLE (TI): Direct Submission  
JOURNAL (SO): Submitted (26-APR-1995) D. Kube, Medizinische  
Klinik I  
der Universitaet zu Koeln, LFI Ebene 4 Raum 508,  
Joseph-Stelzmann-Str 9, 50924 Koeln, FRG  
REFERENCE: 4 (bases 1 to 4181)  
AUTHOR (AU): Kube,D.  
TITLE (TI): Direct Submission  
JOURNAL (SO): Submitted (25-JAN-1996) D. Kube, Medizinische  
Klinik I  
der Universitaet zu Koeln, LFI Ebene 4 Raum 508,  
Joseph-Stelzmann-Str 9, 50924 Koeln, FRG  
REFERENCE: 5 (bases 1 to 4181)  
AUTHOR (AU): Eskdale,J.; Kube,D.; Gallagher,G.  
TITLE (TI): A second polymorphic dinucleotide repeat in the 5'  
flanking region of the human IL10 gene  
JOURNAL (SO): Immunogenetics, 45 (1), 82-83 (1996)  
OTHER SOURCE (OS): CA 126:113969

```

FEATURES (FEAT):
  Feature Key      Location      Qualifier
=====+=====+=====
source            1..4181      /organism="Homo sapiens"

```

mRNA 4023...>4181  
gene 4023...4181  
CDS 4051...>4181

/tissue-type="placenta"  
/clone-lib="pWe15 cosmid library"  
/gene="Il-10"  
/evidence=experimental  
/gene="Il-10"  
/gene="Il-10"  
/codon-start=1  
/product="interleukin-10"  
/db-xref="PID:e220327"  
/db-xref="PID:g1177469"  
/translation="MHSSALLCCLVLLTGVRASP  
GQGTQSENSCTHFPNLPNMLRDL "

## SEQUENCE (SEQ):

```
1 agatcttgta aactgtagaa tgcaccctcc aaaatctatt tgcataagca cacacacaca
61 cacacacaca cacacccag cagttcttgc ctgcccagat tcctctgcag ctaaagtgat
121 gaaacttact gggcggagct tcctaaaaag attattaggg tctcctgggt tgggtgacct
181 ttaaacccttt ggactttacc acctcctatc tctcctatct ccttgcaaca aagggttagga
241 gaacaagaat gcagaaaaaa cgggtcctgg atgacatctg agtgcctgct ttgggcttct
301 tgatgagtga gacagaaaat aaaatacaac cccctctttt aaaagccatg cttactcagg
361 ttttccttca tttgcagcta aatacagaaa tgagagaata ttttgagga gggatggaaag
421 aagagaggta ttccccttcc cacaaccttc tgatttccca gtacatcccc cactggaaaa
481 attcatttaa aatcagtata ataagcattg attagatgcc tactatgcat ctgggcttga
541 gggcaaaactg gactcaggcc ttttggcctc aagaagctca cagtgtgaga gtggcatttg
601 tgcctcttgg aaattcacag gactaaattg tgcccaggct gacattctat ccatccatag
661 gtgcctgcct tctcacttcc ctctcttcat gggctcttgc ctgtaccaaa aatccaaacc
721 caaatctcct cacatgtgag tgttggcatt catgtctcag acatgacctt tgggcttggg
781 acttttcccc gtggacccca gtgacttttc agatgaacag gtatcttcaa aaacttgaga
841 aataggagtc ctgtttgttg ttcttgttgc tttgtcaata taaggcacag ggtctttatt
901 caaatgttca tactatctct tgacagaaat actatgagac atattgatgg agaagccgtt
961 atctccatat gctaaatgag gacttgcacc agggaacttg cccatgggtc tctccaacca
1021 cttaaattct gaaattttga atgagagtgg acagtaattt caaatcaatg gggaaagaat
1081 caaatcttca gcaaatggct tgagataatt agctacacat ttcagaacaa ataaagaagt
1141 cagatccggg ccgggcacag tggctcatgc ctgtaatctc agcactctgg gaggccaagg
1201 cgggcggatc ataaggtcag gagatcgaga ccatcctggg taacacagtg aacctctctc
1261 taataaaaaa acaaaaaaaa ataaaaaac ttagccgggc gtggtgccag gcgcctgtag
1321 tccagctac tcgggacgct gaggcaggag aatggcttga actcgggagg cagagcttgc
1381 aggtgagctg agatcatgcc actgcactcc agcctgggca acagagcgag actctgtctc
1441 aaaaaaaaaa aagaagtcag atcctaacct caacctattt taacagatta tagatgaaag
1501 aaaggtacaa atggctttta catacctccc ttctccctga cattttgtat gtgtgtgtgt
1561 gtgtatttac acacacatct catataagga aattgaaggg aggtgcctg catccctgag
1621 tcaactctcc tctccttctg aatgcttacc tgtgccaga ccacctcctt agcctcgcac
1681 cctccaggct tacagggcac tcttctatgc ccatcccaag tatagctgaa ccttccaagg
1741 gccagacttg gtgctaagta ccaagtacgc aaagattaat aaaacaatg cctgtttcag
1801 ggagctcaaa gctgattcgg cagggcatgg tgtgtacatg aatgataacc acgtggggtt
1861 gcaggtttcc tagtgaggta agcacaaggc aagatgggaa acaaagggaag gagggttca
1921 cagcctcacc cagagtccag aacctctggc ctgcctgggt cccatgctga gtccacttct
1981 ggaacaccca gctcagagag ggggttagac ctgcaggcta acacagacac agcccagaaa
2041 acccaggagc cgagggggaa ggagaaaggt gcaagaaggg gaaacccagg tcctggctcc
2101 cttctctctg cttcctggca gcagaactca gacagaacct ttaagccagt ctaagtctgg
2161 caggaccagt aagttctgag ttagctccat actagtttct agcaggctct ttctcacttc
2221 ctgattctta ggtttctaca ttgacactcc ctgaagagtt ggaagagac accacagtcc
2281 cctgaccctg atccataggt cacacagcag gcatccacag ggtgggcgtg ggccctctca
2341 tccctccctc ccaactcactt cacgtctggt gggccccaag gtgtttgcac cccttgagct
2401 gagtgcactt ctctagtgcg gcaagctcag aacctgctgc cactggagtt gtcccattgc
2461 tgatgcagaa aggtgaagaa ctagcagaac actggaaatg ccctccatct ggggtccatg
2521 ctacttaatg ctccctggca ggcaggagga cagggtgctat tccctgttgg gacagatgaa
2581 aaacagacac agggaggatg agtgatttgc cctgactata gagtggcagg gccaaaggcag
2641 agcccaggcc tcctgcacct aggtcagtggt tcctcccagt tacagtctaa actggaatgc
2701 aggcaaagcc cctgtggaag gggaaggcta aggtcaatc aaaggatccc cagagacttt
2761 ccagatatct gaagaagtcc tgatgtcact gcccggtcc ttcccagatc gagagcaaac
2821 tctctgccgc aacccaactg gctcccctta ccttctacac acacacacac acacacacac
2881 acacacacac acacacacaa atccaagaca aactactaa ggcttcttgg ggaaggggaa
2941 gtagggatag gtaagaggaa agtaagggac ctcttatcca gcctccatgg aatcctgact
3001 tcttttccct gttattttcaa cttcttccac cccatctttt aaactttaga ctccagccac
```

3061 agaagcttac aactaaaaga aactctaagg ccaatttaat ccaaggtttc attctatgtg  
3121 ctggagatgg tgtacagtag ggtgaggaaa ccaaattctc agttggcact ggtgtaccct  
3181 tgtacaggtg atgtaacatc tctgtgcctc agtttgctca ctataaaata gagacggtag  
3241 gggcatggt gagcactacc tgactagcat ataagaagct ttcagcaagt gcgactact  
3301 cttaccctact tcccccaagc acagttgggg tgggggacag ctgaagaggt ggaaacatgt  
3361 gcctgagaat cctaataaaa tcggggtaaa ggagcctgga acacatcctg tgaccccgcc  
3421 tgtcctgtag gaagccagtc tctggaaagt aaaatggaag ggctgcttgg gaactttgag  
3481 gatatttagc ccacccctc atttttactt ggggaaacta aggcccagag acctaagggtg  
3541 actgcctaag ttagcaagga gaagtcttgg gtattcatcc cagggtgggg ggacccaatt  
3601 atttctcaat cccattgtat tctggaatgg gcaatttgtc cacgtcactg tgacctagga  
3661 acacgcgaat gagaacccac agctgagggc ctctgcgcac agaacagctg ttctccccag  
3721 gaaatcaact tttttaatt gagaagctaa aaaattattc taagagaggt agcccatcct  
3781 aaaaatagct gtaatgcaga agttcatgtt caaccaatca tttttgctta cgatgcaaaa  
3841 attgaaaact aagtttatta gagaggtag agaaggagga gctctaagga gaaaaaatcc  
3901 tgtgccggga aaccttgatt gtggcttttt aatgaatgaa gaggcctccc tgagcttaca  
3961 atataaaagg gggacagaga ggtgaaggtc tacacatcag gggcttgctc ttgcaaaacc  
4021 aaaccacaag acagacttgc aaaagaaggc atgcacagct cagcactgct ctgttgctg  
4081 gtccctcctga ctgggtgag ggccagcca ggccaggga cccagctga gaacagctgc  
4141 acccacttcc caggcaacct gcctaacatg cttcgagatc t


**Claims**

1. An adenoviral vector comprising:
  - (a) a mammalian regulatory region; and
  - (b) a reporter gene operatively linked to the mammalian regulatory region (a).
2. An adenoviral vector according to claim 1, wherein the mammalian regulatory region is a cytokine regulatory region.
3. An adenoviral vector according to claim 1 or claim 2, wherein the regulatory region is a promoter or enhancer.
4. An adenoviral vector according to claim 3, wherein the promoter is a TNF $\alpha$  promoter or an IL-10 promoter.
5. An adenoviral promoter according to claim 4, wherein the cytokine promoter is encompassed in -1173 to +130 of the human TNF gene.
6. An adenoviral vector according to any preceding claim, wherein the reporter gene is selected from luciferase, lacZ and chloramphenicol acetyltransferase (CAT).
7. An adenoviral vector according to any preceding claim additionally comprising a polyadenylation site operatively linked 3' to the reporter gene.
8. An adenoviral vector according to any preceding claim, additionally comprising 3' to the reporter gene a 3'-UTR (Untranslated Region).
9. A method of studying a mammalian regulatory region activity comprising inserting an adenoviral vector according to any preceding claim bearing the regulatory region into a cell and measuring the amount of reporter gene product produced in response to the regulatory region.

10. A method according to claim 9, additionally comprising exposing the adenoviral vector within the cell to one or more inhibitors or activators of the regulatory region.
11. A method according to claim 9 or claim 10, wherein the cell is selected from a monocytic cell, macrophage and a primary cell.
12. A method according to claim 11, wherein the primary cell is obtained from diseased tissue.
13. A method according to claim 12, wherein the diseased tissue is rheumatoid arthritic.
14. A cell comprising an adenoviral vector according to any one of claims 1 to 8.
15. A kit for use in a method according to claim 9, comprising an adenoviral vector according to any one of claims 1 to 8.
16. A method of screening a compound as an enhancer or an inhibitor of a mammalian regulatory region, comprising the use of an adenoviral vector according to any one of claims 1-8.




Figure 1




2/10

## Figure 2




3/10

Figure 3




4/10

Figure 4



SUBSTITUTE SHEET (RULE 26)

5/10

**Figure 5**

6/10


**Figure 6**

Figure 7





Figure 8





9/10







Figure 9

10/10

# Figure 10

RAW 264.7 cells

Murine primary  
peritoneal  
macrophage

(19) World Intellectual Property Organization  
International Bureau




(43) International Publication Date  
29 March 2001 (29.03.2001)

PCT

(10) International Publication Number  
**WO 01/21823 A3**

- (51) International Patent Classification<sup>7</sup>: C12N 15/86, 15/24, 15/28
- (21) International Application Number: PCT/GB00/03645
- (22) International Filing Date:  
22 September 2000 (22.09.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
9922283.8 22 September 1999 (22.09.1999) GB
- (71) Applicant (for all designated States except US): THE MATHILDA & TERENCE KENNEDY INSTITUTE OF RHEUMATOLOGY [GB/GB]; 1 Aspenlea Road, Hammersmith, London W6 8LH (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): FELDMAN, Marc [AU/GB]; 2 Church Road, London N6 4QT (GB). FOXWELL, Brian, Maurice, John [GB/GB]; 23 Lansdowne Road, Hownslow, Middlesex TW3 1LQ (GB).
- (74) Agents: ELSY, David et al.; Withers & Rogers, Goldings House, 2 Hays Lane, London SE1 2HW (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
11 October 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ADENOVIRAL VECTOR WITH A REPORTER GENE LINKED TO A REGULATORY REGION



(57) Abstract: The invention relates to adenoviral vectors comprising a mammalian regulatory region such as a cytokine regulatory region and a reporter gene operatively linked to the cytokine promoter. Preferably, the cytokine promoter is a TNF $\alpha$  promoter or an IL-10 promoter. The application also discloses methods of studying cytokine promoter activity and to cells containing the adenoviral vectors.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/03645

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/86 C12N15/24 C12N15/28

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, BIOSIS, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	UDALOVA ET AL: "Complex NF-kB interactions at the distal tumor necrosis factor promoter region in human monocytes" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, 1998, pages 21178-21186, XP002162886 cited in the application * Page 21178 (Introduction); page 21179; plasmid (hTNF promoter sequence); page 21184 (Discussion) *	1-16
Y	BONDESON ET AL: "Adenoviral transfer of the Ikb gene inhibits the induction of proinflammatory cytokines" ARTHRITIS & RHEUMATISM, vol. 40, September 1997 (1997-09), page S322 XP000981222 * Abstract *	1-16



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

19 March 2001

Date of mailing of the international search report

30/03/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Korsner, S-E

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/03645

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>ROBERT ET AL.: "An adenoviral vector-based system to study neuronal gene expression: Analysis of the rat tyrosine hydroxylase promoter in cultured neurons" JOURNAL OF NEUROCHEMISTRY, vol. 68, 1997, pages 2152-2160, XP000989957</p> <p>* Page 2152 (column 2) - page 2153 (column 1); figure 1; pages 2157-2159 (Discussion) *</p> <p style="text-align: center;">---</p>	1-16
A	<p>KAWASAKI ET AL.: "Selection of the best target site for ribozyme-mediated cleavage within a fusion gene for adenovirus E1A-associated 300 kDa protein (p300) and luciferase" NUCLEIC ACIDS RESEARCH, vol. 24, 1996, pages 3010-3016, XP002162887</p> <p>* Page 3013, column 1 *</p> <p style="text-align: center;">---</p>	1-16
A	<p>WO 99 09045 A (SOMAGENICS) 25 February 1999 (1999-02-25) * Example I(C); Figure 4 *</p> <p style="text-align: center;">---</p>	1-16
Y,P	<p>NETTELBECK ET AL.: "GENE THERAPY / Designer promoters for tumour targeting" TIG, vol. 16, April 2000 (2000-04), pages 174-181, XP002162888</p> <p>* Tables &amp; figures *</p> <p style="text-align: center;">-----</p>	1-16

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/03645

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9909045 A	25-02-1999	AU 9199998 A EP 1019429 A	08-03-1999 19-07-2000
<hr/>			